<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2022-03-11T00:50:24Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8536357" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8536357</identifier>
        <datestamp>2021-10-27</datestamp>
        <setSpec>pnas</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
              <journal-id journal-id-type="iso-abbrev">Proc Natl Acad Sci U S A</journal-id>
              <journal-id journal-id-type="hwp">pnas</journal-id>
              <journal-id journal-id-type="publisher-id">PNAS</journal-id>
              <journal-title-group>
                <journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0027-8424</issn>
              <issn pub-type="epub">1091-6490</issn>
              <publisher>
                <publisher-name>National Academy of Sciences</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8536357</article-id>
              <article-id pub-id-type="pmcid">PMC8536357</article-id>
              <article-id pub-id-type="pmc-uid">8536357</article-id>
              <article-id pub-id-type="pmid">34408076</article-id>
              <article-id pub-id-type="pmid">34408076</article-id>
              <article-id pub-id-type="publisher-id">202104640</article-id>
              <article-id pub-id-type="doi">10.1073/pnas.2104640118</article-id>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>404</subject>
                  <subject>535</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Physical Sciences</subject>
                  <subj-group>
                    <subject>Applied Mathematics</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1340-965X</contrib-id>
                  <name>
                    <surname>Silva</surname>
                    <given-names>Paulo J. S.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9363-9297</contrib-id>
                  <name>
                    <surname>Sagastizábal</surname>
                    <given-names>Claudia</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nonato</surname>
                    <given-names>Luís Gustavo</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2114-847X</contrib-id>
                  <name>
                    <surname>Struchiner</surname>
                    <given-names>Claudio José</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pereira</surname>
                    <given-names>Tiago</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><sup>a</sup>Instituto de Matemática, Estatística e Computação Científica, <institution>Universidade Estadual de Campinas</institution>, 13083-859 São Paulo, <country>Brazil</country>;</aff>
                <aff id="aff2"><sup>b</sup>Instituto de Ciências Matemáticas e Computação, <institution>Universidade de São Paulo</institution>, 13566-590 São Paulo, <country>Brazil</country>;</aff>
                <aff id="aff3"><sup>c</sup><institution>Escola de Matemática Aplicada, Fundação Getúlio Vargas</institution>, 22250-9 Rio de Janeiro, <country>Brazil</country></aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><sup>1</sup>To whom correspondence may be addressed. Email: <email>tiago@icmc.usp.br</email>.</corresp>
                <fn fn-type="edited-by">
                  <p>Edited by David L. Donoho, Stanford University, Stanford, CA, and approved July 8, 2021 (received for review March 12, 2021)</p>
                </fn>
                <fn fn-type="con">
                  <p>Author contributions: P.J.S.S., C.S., C.J.S., and T.P. designed research; P.J.S.S., C.S., C.J.S., and T.P. performed research; C.S. contributed new reagents/analytic tools; P.J.S.S., C.S., L.G.N., C.J.S., and T.P. analyzed data; and P.J.S.S., C.S., C.J.S., and T.P. wrote the paper.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>31</day>
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>18</day>
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>18</day>
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <volume>118</volume>
              <issue>35</issue>
              <elocation-id>e2104640118</elocation-id>
              <permissions>
                <copyright-statement>Copyright © 2021 the Author(s). Published by PNAS.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This open access article is distributed under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="pnas.202104640.pdf"/>
              <abstract abstract-type="executive-summary">
                <title>Significance</title>
                <p>Shortages of COVID-19 vaccines hampered efforts to fight the current pandemic, leading experts to argue for delaying the second dose to provide earlier first-dose protection to twice as many people. We designed a model-based strategy for identifying the optimal second-dose delay using the hospitalization rate as the key metric. While epistemic uncertainties apply to our modeling, we found that the optimal delay was dependent on first-dose efficacy and vaccine mechanism of action. For infection-blocking vaccines, the second dose could be delayed <inline-formula><mml:math id="i1" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>8 weeks if the first-dose efficacy was <inline-formula><mml:math id="i2" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>50%. For symptom-alleviating vaccines, this delay duration is recommended if the first-dose efficacy was <inline-formula><mml:math id="i3" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>70%. These results suggest that delaying the second vaccine dose is a feasible option.</p>
              </abstract>
              <abstract>
                <p>Slower than anticipated, COVID-19 vaccine production and distribution have impaired efforts to curtail the current pandemic. The standard administration schedule for most COVID-19 vaccines currently approved is two doses administered 3 to 4 wk apart. To increase the number of individuals with partial protection, some governments are considering delaying the second vaccine dose. However, the delay duration must take into account crucial factors, such as the degree of protection conferred by a single dose, the anticipated vaccine supply pipeline, and the potential emergence of more virulent COVID-19 variants. To help guide decision-making, we propose here an optimization model based on extended susceptible, exposed, infectious, and removed (SEIR) dynamics that determines the optimal delay duration between the first and second COVID-19 vaccine doses. The model assumes lenient social distancing and uses intensive care unit (ICU) admission as a key metric while selecting the optimal duration between doses vs. the standard 4-wk delay. While epistemic uncertainties apply to the interpretation of simulation outputs, we found that the delay is dependent on the vaccine mechanism of action and first-dose efficacy. For infection-blocking vaccines with first-dose efficacy <inline-formula><mml:math id="i4" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>50%, the model predicts that the second dose can be delayed by <inline-formula><mml:math id="i5" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>8 wk (half of the maximal delay), whereas for symptom-alleviating vaccines, the same delay is recommended only if the first-dose efficacy is <inline-formula><mml:math id="i6" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>70%. Our model predicts that a 12-wk second-dose delay of an infection-blocking vaccine with a first-dose efficacy <inline-formula><mml:math id="i7" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>70% could reduce ICU admissions by 400 people per million over 200 d.</p>
              </abstract>
              <kwd-group>
                <kwd>outbreaks</kwd>
                <kwd>vaccination</kwd>
                <kwd>control</kwd>
                <kwd>strategies</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="gs1">
                  <funding-source id="sp1">Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)<named-content content-type="funder-id">501100001807</named-content></funding-source>
                  <award-id rid="sp1">2013/07375-0</award-id>
                  <principal-award-recipient>Paulo JS Silva</principal-award-recipient>
                  <principal-award-recipient>Claudia Sagastizábal</principal-award-recipient>
                  <principal-award-recipient>Luis Gustavo Nonato</principal-award-recipient>
                  <principal-award-recipient>Tiago Pereira</principal-award-recipient>
                </award-group>
                <award-group id="gs2">
                  <funding-source id="sp2">Royal Society<named-content content-type="funder-id">501100000288</named-content></funding-source>
                  <award-id rid="sp2">NAFR1180236</award-id>
                  <principal-award-recipient>Tiago Pereira</principal-award-recipient>
                </award-group>
                <award-group id="gs3">
                  <funding-source id="sp3">MCTI | Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)<named-content content-type="funder-id">501100003593</named-content></funding-source>
                  <award-id rid="sp3">301778/2017-5</award-id>
                  <principal-award-recipient>Paulo JS Silva</principal-award-recipient>
                  <principal-award-recipient>Claudia Sagastizábal</principal-award-recipient>
                  <principal-award-recipient>Luis Gustavo Nonato</principal-award-recipient>
                  <principal-award-recipient>Claudio Jose Struchiner</principal-award-recipient>
                  <principal-award-recipient>Tiago Pereira</principal-award-recipient>
                </award-group>
                <award-group id="gs4">
                  <funding-source id="sp4">MCTI | Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)<named-content content-type="funder-id">501100003593</named-content></funding-source>
                  <award-id rid="sp4">302836/2018-7</award-id>
                  <principal-award-recipient>Paulo JS Silva</principal-award-recipient>
                  <principal-award-recipient>Claudia Sagastizábal</principal-award-recipient>
                  <principal-award-recipient>Luis Gustavo Nonato</principal-award-recipient>
                  <principal-award-recipient>Claudio Jose Struchiner</principal-award-recipient>
                  <principal-award-recipient>Tiago Pereira</principal-award-recipient>
                </award-group>
                <award-group id="gs5">
                  <funding-source id="sp5">MCTI | Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)<named-content content-type="funder-id">501100003593</named-content></funding-source>
                  <award-id rid="sp5">304301/2019-1</award-id>
                  <principal-award-recipient>Paulo JS Silva</principal-award-recipient>
                  <principal-award-recipient>Claudia Sagastizábal</principal-award-recipient>
                  <principal-award-recipient>Luis Gustavo Nonato</principal-award-recipient>
                  <principal-award-recipient>Claudio Jose Struchiner</principal-award-recipient>
                  <principal-award-recipient>Tiago Pereira</principal-award-recipient>
                </award-group>
                <award-group id="gs6">
                  <funding-source id="sp6">MCTI | Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)<named-content content-type="funder-id">501100003593</named-content></funding-source>
                  <award-id rid="sp6">302912/2019-3</award-id>
                  <principal-award-recipient>Paulo JS Silva</principal-award-recipient>
                  <principal-award-recipient>Claudia Sagastizábal</principal-award-recipient>
                  <principal-award-recipient>Luis Gustavo Nonato</principal-award-recipient>
                  <principal-award-recipient>Claudio Jose Struchiner</principal-award-recipient>
                  <principal-award-recipient>Tiago Pereira</principal-award-recipient>
                </award-group>
                <award-group id="gs7">
                  <funding-source id="sp7">MCTI | Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)<named-content content-type="funder-id">501100003593</named-content></funding-source>
                  <award-id rid="sp7">403679/2020-6</award-id>
                  <principal-award-recipient>Paulo JS Silva</principal-award-recipient>
                  <principal-award-recipient>Claudia Sagastizábal</principal-award-recipient>
                  <principal-award-recipient>Luis Gustavo Nonato</principal-award-recipient>
                  <principal-award-recipient>Claudio Jose Struchiner</principal-award-recipient>
                  <principal-award-recipient>Tiago Pereira</principal-award-recipient>
                </award-group>
                <award-group id="gs8">
                  <funding-source id="sp8">Serrapilheira Institute</funding-source>
                  <award-id rid="sp8">Serra-1709-16124</award-id>
                  <principal-award-recipient>Tiago Pereira</principal-award-recipient>
                </award-group>
                <award-group id="gs9">
                  <funding-source id="sp9">Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)<named-content content-type="funder-id">501100004586</named-content></funding-source>
                  <award-id rid="sp9">E-26/202.828/2017</award-id>
                  <principal-award-recipient>Claudio Jose Struchiner</principal-award-recipient>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="8"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p content-type="flushleft">Immunization of a large proportion of the worldwide population against the severe acute respiratory syndrome coronavirus 2 (COVID-19) is the most pressing current public health concern globally. Despite the unprecedented speed at which safe and effective vaccines were developed, tested, and approved, slower than anticipated vaccine production and distribution have hampered efforts to curtail the ongoing pandemic (<xref rid="r1" ref-type="bibr">1</xref><xref rid="r2" ref-type="bibr"/>–<xref rid="r3" ref-type="bibr">3</xref>). The delays have not only resulted in an alarming number of potentially preventable deaths but also, contributed to the emergence of more virulent strains that could reduce the efficacy of current vaccines (<xref rid="r4" ref-type="bibr">4</xref>). Of the eight COVID-19 vaccines currently authorized around the globe, most have a recommended schedule of two doses separated by 3 to 4 wk. While awaiting replenishment of vaccine supplies, some governments are considering or have implemented delayed administration of the second vaccine dose in order to increase the proportion of the population with at least partial protection from a single dose. Recent debates argue in favor of such delay strategies (<xref rid="r1" ref-type="bibr">1</xref><xref rid="r2" ref-type="bibr"/>–<xref rid="r3" ref-type="bibr">3</xref>), but there are no guidelines as to how the optimal delay duration should be determined, and this has yet to be tested in clinical trials. Two major questions are the extent to which delaying the second dose would impact hospitalization rates and alleviate mitigation measures when compared with the standard 3- to 4-wk second-dose delay.</p>
            <p>Here, we report a model-based strategy for identifying the optimal delay time between vaccine doses using intensive care unit (ICU) hospitalizations as the key metric. We show that the optimal time is influenced by both the first-dose efficacy and whether the vaccine prevents infection or alleviates symptoms. The decision to delay the second vaccine dose is therefore not trivial because single doses of infection-blocking and disease-modifying vaccines are unlikely to have an equivalent impact on curbing the pandemic (<xref rid="r5" ref-type="bibr">5</xref>), and a large number of infection scenarios and their effect on disease evolution must also be taken into account.</p>
            <p>To assist in decision-making about the optimal time to delay the second COVID-19 vaccine dose, we extended the susceptible, exposed, infectious, and removed (SEIR) model to include vaccination campaigns with two doses across populations. The epidemiological dynamic is used to predict ICU bed occupancy as a stochastic process that follows the disease trajectory. This information feeds a larger model that maintains the ICU occupancy within the operational capacity by restricting population circulation when needed. This is a unique feature of our approach, as other efforts to determine optimal dosing schedules for the COVID-19 vaccines do not take into account social distancing (<xref rid="r6" ref-type="bibr">6</xref><xref rid="r7" ref-type="bibr"/>–<xref rid="r8" ref-type="bibr">8</xref>). We describe an optimization algorithm to find the best vaccination regimen that does not increase hospitalization rates while successfully alleviating social distancing and travel restrictions, thereby accelerating a return to “normality” as soon as possible.</p>
            <sec id="s1">
              <title>1. Results</title>
              <p content-type="flushleft">The algorithm explores multiple scenarios to obtain the best profile for delaying the second vaccine dose while safeguarding the health care system and lessening mitigation measures. The second-dose delay mechanism is not explicit but emerges from the solution of the optimization, and the solver decides when to administer the second dose. As illustrated in <xref rid="fig01" ref-type="fig">Fig. 1</xref>, several factors are taken into account: age, mechanism of vaccine action (symptom alleviation vs. infection prevention), vaccine availability, ICU capacity and its variability, and ICU hospitalization rates among different age groups.</p>
              <fig position="float" id="fig01" fig-type="featured">
                <label>Fig. 1.</label>
                <caption>
                  <p>A mathematical model combines data and optimization to obtain an optimal delay for administration of a vaccine second dose. The optimal second-dose delay emerges from the solution of the optimization model. The model blends ICU usage data, the vaccine mechanism of action, vaccine availability, and population demographics into an epidemiological model to predict future ICU admissions by age group. The model is solved using an optimization algorithm that considers multiple scenarios and iteratively adjusts the decision variables to find the optimal delay between the first and second vaccine doses and the target control reproduction number. The graphics used to prepare <xref rid="fig01" ref-type="fig">Fig. 1</xref> are extracted from Freepik.</p>
                </caption>
                <graphic xlink:href="pnas.2104640118fig01" id="gra1" position="float"/>
              </fig>
              <p>To illustrate, consider a single age group. At each incremental change in delay time, there are three decision variables: 1) the reproduction number <inline-formula><mml:math id="i8" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, 2) the number of first doses currently administered, and 3) the number of second doses currently administered. Reducing mitigation measures (i.e., increasing <inline-formula><mml:math id="i9" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>) increases the number of ICU admissions, whereas increasing the vaccination rate has the opposite effect. However, a certain time delay between first and second doses may be beneficial depending on the protection level conferred by the first dose. Each iteration of the solution method adjusts the control variables taking into account the dynamics, the logistic constraints, and the ICU capacity. The adjustment is performed in a manner that favors large reproduction numbers <inline-formula><mml:math id="i10" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. We can then compute a second-dose delay for all time steps to obtain the optimal delay.</p>
              <sec id="s2">
                <title>1A. Multiple Subpopulation SEIR Model with Two Vaccine States.</title>
                <p>We extend the SEIR model to include individuals receiving vaccines.</p>
                <p>Given a subpopulation <inline-formula><mml:math id="i11" overflow="scroll"><mml:mi>p</mml:mi></mml:math></inline-formula>, the proportions of the susceptible subpopulation that have received zero, one, and two vaccine doses are <inline-formula><mml:math id="i12" overflow="scroll"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="i13" overflow="scroll"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, respectively. The other SEIR states, <inline-formula><mml:math id="i14" overflow="scroll"><mml:mi>E</mml:mi><mml:mo>,</mml:mo></mml:math></inline-formula>
<inline-formula><mml:math id="i15" overflow="scroll"><mml:mi>I</mml:mi></mml:math></inline-formula>, and <inline-formula><mml:math id="i16" overflow="scroll"><mml:mi>R</mml:mi></mml:math></inline-formula>, were also similarly split. The parameters <inline-formula><mml:math id="i17" overflow="scroll"><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>0,1</mml:mn></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:math></inline-formula> decrease the probability that a vaccinated individual will be infected when exposed to an infected individual, considering one and two doses, respectively, while <inline-formula><mml:math id="i18" overflow="scroll"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="i19" overflow="scroll"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> represent the proportions of individuals who have received first and second doses. The model is presented in <xref rid="s13" ref-type="sec"><italic toggle="yes">Methods</italic></xref>, and the interactions are illustrated in <xref rid="fig01" ref-type="fig">Fig. 1</xref>. The main elements of our optimization model are described below.</p>
                <sec id="s3">
                  <title>1A.1. Groups in the population.</title>
                  <p>We stratify the population into subgroups with specific demands on health care. We considered four age groups of 0 to 19, 20 to 49, 50 to 64, and 65 to 90 y in groups 1, 2, 3, and 4, respectively. The contact matrix <inline-formula><mml:math id="i20" overflow="scroll"><mml:mi>C</mml:mi></mml:math></inline-formula> between age groups is presented in <xref rid="s13" ref-type="sec"><italic toggle="yes">Methods</italic></xref>. We set the initial condition as <inline-formula><mml:math id="i21" overflow="scroll"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>68.5</mml:mn></mml:math></inline-formula>%, <inline-formula><mml:math id="i22" overflow="scroll"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1.0</mml:mn></mml:math></inline-formula>%, <inline-formula><mml:math id="i23" overflow="scroll"><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.6</mml:mn></mml:math></inline-formula>%, and <inline-formula><mml:math id="i24" overflow="scroll"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>29.9</mml:mn></mml:math></inline-formula>%, corresponding to typical values for multiple countries at the beginning of February 2021. The algorithm was run with basal reproduction number <inline-formula><mml:math id="i25" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> ranging between 1.8 and 3.0 without observing a significant change in the output decisions. The subpopulation breakdown by age is 30, 48, 14, and 8% for groups 1, 2, 3, and 4, respectively.</p>
                  <p>Given a reproduction number <inline-formula><mml:math id="i26" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, the reproduction number of the subpopulation <inline-formula><mml:math id="i27" overflow="scroll"><mml:mi>p</mml:mi></mml:math></inline-formula> is the product <inline-formula><mml:math id="i28" overflow="scroll"><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, where factor <inline-formula><mml:math id="i29" overflow="scroll"><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> represents subpopulation susceptibility that is greater than or equal to that of the overall population. This factor is one except for <inline-formula><mml:math id="i30" overflow="scroll"><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1.3</mml:mn></mml:math></inline-formula>, which takes into account the increased mobility and thus, contribution to disease transmission by the 20- to 49-y-old age group.</p>
                </sec>
                <sec id="s4">
                  <title>1A.2. Objectives.</title>
                  <p>To prevent collapse of the health care system, the reproduction number must be decreased. This can be achieved by restricting circulation and implementing a vaccination campaign: that is, deciding for each day <inline-formula><mml:math id="i31" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula> and subpopulation <inline-formula><mml:math id="i32" overflow="scroll"><mml:mi>p</mml:mi></mml:math></inline-formula> the values of <inline-formula><mml:math id="i33" overflow="scroll"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="i34" overflow="scroll"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> (<xref rid="r9" ref-type="bibr">9</xref>, <xref rid="r10" ref-type="bibr">10</xref>) until the reproduction number reaches a target value <inline-formula><mml:math id="i35" overflow="scroll"><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula>.</p>
                  <p>Rather than performing simulations of known case studies defined by experts (<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>) in our model, the optimization algorithm drives selection of the best strategy by considering implicitly all possible combinations of social distancing and vaccination profiles. Accordingly, the optimization model casts <inline-formula><mml:math id="i36" overflow="scroll"><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="i37" overflow="scroll"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="i38" overflow="scroll"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> as decision variables to be selected by the algorithm among all scenarios that combines mitigation measure and vaccine administration to save ICU admissions. The choices range from complete lockdown <inline-formula><mml:math id="i39" overflow="scroll"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> to free circulation <inline-formula><mml:math id="i40" overflow="scroll"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> in combination with single-dose administration to any or no portion of a population (<inline-formula><mml:math id="i41" overflow="scroll"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>0,1</mml:mn></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:math></inline-formula>), and similarly for the second dose (<inline-formula><mml:math id="i42" overflow="scroll"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>0,1</mml:mn></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:math></inline-formula>). To determine the best strategy, the optimization process is guided by its objective function that encourages higher values of <inline-formula><mml:math id="i43" overflow="scroll"><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> and translates into a more freely circulating population. For logistic reasons, the objective function also includes a term that promotes smooth changes in the vaccination profile.</p>
                  <p>The optimization model also takes into account ICU occupancy and maintains it below maximum capacity with a 95% probability. The number of ICU patients on day <inline-formula><mml:math id="i44" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula> follows a stochastic process calibrated as a time series for the proportion of infected individuals who will need intensive care on day <inline-formula><mml:math id="i45" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula>. We estimate that the average stay in the ICU is 7 d (<xref rid="r11" ref-type="bibr">11</xref>). Using official records for Brazil for the last quarter of 2020, we computed the mean number of patients in the ICU for each day <italic toggle="yes">t</italic> between day <inline-formula><mml:math id="i46" overflow="scroll"><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:mn>7</mml:mn></mml:math></inline-formula> and day <inline-formula><mml:math id="i47" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula> and divided that by the number of new cases reported in day <italic toggle="yes">t</italic>. After the time series is calibrated for the ratio, knowing the number of infected individuals in the SEIR dynamics at day <inline-formula><mml:math id="i48" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula> gives a stochastic trajectory of ICU bed occupancy from which we derive a probabilistic constraint. The considered ICU bed capacity is 17.5 per 100,000 inhabitants, and the mean ICU bed demand is 1.2% (SD 0.64%) of the infected population, distributing the values among the age groups.</p>
                </sec>
                <sec id="s5">
                  <title>1A.3. Vaccine mechanisms.</title>
                  <p>We consider two types of vaccine (<xref rid="r5" ref-type="bibr">5</xref>): infection blocking and symptom alleviating. An infection-blocking vaccine can prevent infection by decreasing the likelihood of becoming infected from an encounter with an infectious individual by one minus the dose efficacy. This is modeled by multiplying the respective reproduction number by this factor, represented by the parameters <inline-formula><mml:math id="i49" overflow="scroll"><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="i50" overflow="scroll"><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> in the model. In the case of a vaccine that alleviates symptoms, we keep <inline-formula><mml:math id="i51" overflow="scroll"><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula> and assume that the effect of the vaccine is only to decrease the likelihood of an infected individual requiring ICU admission. This is modeled by multiplying the estimate of ICU beds needed for vaccinated individuals by one minus the dose efficacy.</p>
                </sec>
                <sec id="s6">
                  <title>1A.4. Profile of available doses.</title>
                  <p>Available dose numbers are given as a proportion of the population size, with an initial number of 0.1% ramping up linearly to 1.0% over 150 d and remaining constant thereafter. Small modifications to this profile do not affect the main results.</p>
                </sec>
              </sec>
              <sec id="s7">
                <title>1B. Standard Vaccination by Age Groups as Baseline.</title>
                <p>For both types of vaccine mechanisms over a period of 364 d, we first performed a simulation in which the standard two-dose vaccination strategy is administered to the most at-risk age group (65 to 90 y) first. As a “baseline” strategy, the second dose is automatically reserved for administration 4 wk later, and subpopulations are parsed in order of decreasing age. To evaluate the benefits of postponing the second dose, we used the number of ICU admissions as a measure of benefit gained by optimization of the vaccination strategy compared with the baseline strategy. A complementary metric is to assess the closeness of the reproduction number <inline-formula><mml:math id="i52" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> to the maximum value <inline-formula><mml:math id="i53" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> = 2.5. Since a value of 2.5 represents no circulation restriction, closeness to <inline-formula><mml:math id="i54" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> reflects proximity to an “open society” without enforced mitigation measures.</p>
              </sec>
              <sec id="s8">
                <title>1C. Delaying the Second Dose.</title>
                <p>To address whether delaying the second vaccine dose is desirable, the optimization model determines the best combination of target reproduction number <inline-formula><mml:math id="i55" overflow="scroll"><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> and vaccine distribution among the age groups. In our model, the second dose can be administered at any time up to 12 wk after the first dose.</p>
                <sec id="s9">
                  <title>1C.1. Impact of first-dose efficacy and the vaccine mechanism.</title>
                  <p>We fixed the second-dose efficacy at <inline-formula><mml:math id="i56" overflow="scroll"><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>82.4</mml:mn></mml:math></inline-formula>%, as observed for the AstraZeneca Oxford vaccine (AZD1222) (<xref rid="r12" ref-type="bibr">12</xref>), and let the first-dose efficacy <inline-formula><mml:math id="i57" overflow="scroll"><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> vary from 0 to <inline-formula><mml:math id="i58" overflow="scroll"><mml:mn>80</mml:mn><mml:mi>%</mml:mi></mml:math></inline-formula> in steps of 5%. The goals are 1) to determine if an optimal delay exists (other than the standard 4 wk) and 2) to determine if a threshold exists that would trigger a switch in the best delay time from the recommended (i.e., 4 wk) to as late as possible (12 wk).</p>
                  <p>The results for infection-blocking and symptom-alleviating vaccines are shown in <xref rid="fig02" ref-type="fig">Fig. 2</xref>, where the dotted lines mark the delay at <inline-formula><mml:math id="i59" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2.5</mml:mn></mml:math></inline-formula> and the whiskers correspond to all possible values when <inline-formula><mml:math id="i60" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is varied from 1.8 to 3 in 0.2 steps. For <inline-formula><mml:math id="i61" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> across this range, the threshold efficacy to obtain herd immunity (defined as the point at which the effective reproduction number is below one) ranges from 44.4 to 66.6%. For example, for <inline-formula><mml:math id="i62" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1.8</mml:mn></mml:math></inline-formula>, the model predicts that a fully open society can be reached by week 5, well before the maximum allowed delay for the second dose (12 wk). In contrast, for <inline-formula><mml:math id="i63" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>3.0</mml:mn></mml:math></inline-formula>, the model predicts that mitigation measures will still be required beyond 12 wk. The decision to postpone the second dose is robust across the considered reproduction numbers. These results show that the vaccine mechanism plays a major role in the decision. Thus, when the vaccine blocks infections, the algorithm suggests that the second dose can be delayed by <inline-formula><mml:math id="i64" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>8 wk if the first-dose efficacy is <inline-formula><mml:math id="i65" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula> 50% and by the maximum delay of 12 wk if the first-dose efficacy is <inline-formula><mml:math id="i66" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula> 70%, whereas a delay <inline-formula><mml:math id="i67" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula> 8 wk is advisable for symptom-alleviating vaccines only when the first-dose efficacy is <inline-formula><mml:math id="i68" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula> 70%.</p>
                  <fig position="float" id="fig02" fig-type="figure">
                    <label>Fig. 2.</label>
                    <caption>
                      <p>Optimization of the delay between the first and second doses of a COVID-19 vaccine based on first-dose efficacy and vaccine mechanism. The shaded areas represent the first-dose efficacy that results in doubling the time to second dose from the baseline (4 wk). <italic toggle="yes">Left</italic> shows the second-dose delay when the vaccine alleviates symptoms; in this case, the best strategy delays the second dose for <inline-formula><mml:math id="i69" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>8 wk when the first-dose efficacy is <inline-formula><mml:math id="i70" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>70%. <italic toggle="yes">Right</italic> shows the second-dose delay when the vaccine blocks infection; here, the best strategy delays the second dose for <inline-formula><mml:math id="i71" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>8 wk when the first-dose efficacy is <inline-formula><mml:math id="i72" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>50%. For both vaccine types, the second-dose efficacy reaches 82.4%. The filled circles show the time to the second dose for <inline-formula><mml:math id="i73" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2.5</mml:mn></mml:math></inline-formula>, and the bars represent the variability across simulations when <inline-formula><mml:math id="i74" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is varied from 1.8 to 3 in 0.2 steps.</p>
                    </caption>
                    <graphic xlink:href="pnas.2104640118fig02" id="gra2" position="float"/>
                  </fig>
                </sec>
                <sec id="s10">
                  <title>1C.2. Effect of augmented transmission in a subpopulation.</title>
                  <p>Individuals within specific age groups may play a more active role than other age groups in spreading the disease due to a higher degree of social activity or less stringent attention to sanitary measures. For this analysis, we considered people in the 20- to 49-y-old age group, most of whom would be working and socially active. We fix <inline-formula><mml:math id="i75" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> at 2.5 and compute the second-dose timing as a function of the first-dose efficacy for <inline-formula><mml:math id="i76" overflow="scroll"><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> ranging from 1 to 1.6. We observed only a small variability in the optimal time to second dose; in fact, all curves fell within the shaded area of <xref rid="fig02" ref-type="fig">Fig. 2</xref>. Thus, postponing the second dose is robust with respect to changes in both <inline-formula><mml:math id="i77" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and the reproduction number of specific subpopulations.</p>
                </sec>
                <sec id="s11">
                  <title>1C.3. Comparison between the optimally delayed second dose and baseline strategy.</title>
                  <p>We let <inline-formula><mml:math id="i78" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2.5</mml:mn></mml:math></inline-formula> for all age groups except the 20- to 49-y-old group, where <inline-formula><mml:math id="i79" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> was set 30% higher. We fixed the first- and second-dose efficacies at 76 and 82.4%, respectively, as estimated for the AZD1222 vaccine (<xref rid="r12" ref-type="bibr">12</xref>).</p>
                  <p>To quantify the effect of delaying the second dose on health, we computed the difference in ICU demand when comparing the optimization model and baseline strategies. We varied the efficacy of the first dose from 0 to 80% and determined the impact on COVID-19–related ICU admissions over a specific period, which we set here as 200 d. The algorithm finds an optimal second-dose delay in which social distancing values are no worse than those with the baseline strategy. To achieve this, the model includes the mean baseline <inline-formula><mml:math id="i80" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> as a lower bound and runs the optimization problem with a metric that decreases the overall ICU usage.</p>
                  <p>The results for the first 200 d are reported in <xref rid="fig03" ref-type="fig">Fig. 3</xref>. The data show that a second-dose delay beyond the standard 4 wk will result in a progressive reduction in ICU admissions as the first-dose efficacy increases, with a threshold of 50%. As a comparison, this model would predict that for an infection-blocking vaccine such as AZD1222, which has an actual first-dose efficacy of about 76%, an optimized second-dose delay would save 45 ICU admissions per 100,000 individuals compared with the baseline strategy.</p>
                  <fig position="float" id="fig03" fig-type="figure">
                    <label>Fig. 3.</label>
                    <caption>
                      <p>Reduction in ICU occupancy using the optimized second-dose delay strategy compared with the standard delay strategy. The graph shows the predicted reduction in ICU admissions when the first-dose efficacy is varied from 0 to 80% in 5% increments and is normalized to the baseline strategy of 4 wk between doses.</p>
                    </caption>
                    <graphic xlink:href="pnas.2104640118fig03" id="gra3" position="float"/>
                  </fig>
                  <p>Assuming a first-dose efficacy of <inline-formula><mml:math id="i81" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>50%, the optimization model indicates that each 6% increase in first-dose efficacy reduces the number of ICU admissions by 10 per 100,000 individuals for infection-blocking vaccines and 8 per 100,000 individuals for symptom-alleviating vaccines.The optimized second-dose delay strategy is also supported by complementary metrics that examine the extent to which the vaccination campaign leads progressively to a fully open society. Whereas the baseline strategy results in three periods of 2 wk each of strict lockdown, an optimized second-dose delay of 12 wk results in a single initial lockdown of 2 wk followed by a gradual relaxation of social distancing measures. Thus, the optimization model predicts that a second-dose delay would be beneficial not only in reducing the burden on the health care system but also, in accelerating the return of society to a normal lifestyle.</p>
                </sec>
              </sec>
            </sec>
            <sec id="s12">
              <title>2. Discussion</title>
              <p content-type="flushleft">We developed a model to examine the impact of optimizing the delay between doses of a two-dose COVID-19 vaccine on ICU admissions and societal restrictions compared with a standard delay of 4 wk. Our study demonstrates that the mechanism of vaccine action has a profound effect on the delay. Thus, if the vaccine blocks infection with a first-dose efficacy of <inline-formula><mml:math id="i82" overflow="scroll"><mml:mo>≥</mml:mo></mml:math></inline-formula>50%, the second dose can be delayed by at least 8 wk after the first dose (half of the maximal delay allowed). In contrast, the same delay would be advisable for a symptom-alleviating vaccine only if the first-dose efficacy is at least 70%.</p>
              <p>Strategies to extend the reach of available vaccine supplies, such as halving the dose or increasing the delay interval between doses as considered here, could have a significant beneficial effect on disease transmission and mortality until vaccine supplies increase (<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>). Critics of these strategies fear that induced immunity may wane before the second dose can be administered or result in weak immunity that would favor the emergence of variant strains with higher virulence (<xref rid="r13" ref-type="bibr">13</xref>). However, even partial immunity may reduce disease and/or infection and concomitantly lessen the opportunity for viral mutation and propagation (<xref rid="r14" ref-type="bibr">14</xref><xref rid="r15" ref-type="bibr"/><xref rid="r16" ref-type="bibr"/>–<xref rid="r17" ref-type="bibr">17</xref>).</p>
              <p>Our findings suggest that several societal benefits can be obtained by delaying the second dose of a vaccine, especially if the first-dose efficacy is high (e.g., 76% for AZD1222). First, an optimized delay could lead to a massive reduction in the number of ICU admissions. Given that ICU mortality rates for COVID-19 have reached about 60% in some countries (<xref rid="r18" ref-type="bibr">18</xref>), our findings suggest that an optimized second-dose delay for infection-blocking and symptom-alleviating vaccines could save 90,000 and 40,000 lives, respectively, over 200 d in a country with 300 million inhabitants. The second benefit obtained by an optimized second-dose delay is the extent to which it reduces mitigation measures. Our model predicts a reduction in full lockdowns from three 2-wk lockdowns when using the standard second-dose delay of 4 wk to a single 2-wk lockdown followed by a gradual social distancing relaxation with the optimized delay. Thus, a second-dose delay can save lives and accelerate the return to free circulation.</p>
            </sec>
            <sec sec-type="materials|methods" id="s13">
              <title>3. Methods</title>
              <sec id="s14">
                <title>3A. SEIR Model with Multiple Doses of Vaccine.</title>
                <p>First, we discuss the SEIR dynamic when a two-dose vaccination campaign is put in place. For a fixed population <inline-formula><mml:math id="i83" overflow="scroll"><mml:mi>p</mml:mi></mml:math></inline-formula> and a vaccine mechanism that blocks transmission, we consider the diagram represented by <xref rid="fig04" ref-type="fig">Fig. 4</xref>.</p>
                <fig position="float" id="fig04" fig-type="figure">
                  <label>Fig. 4.</label>
                  <caption>
                    <p>SEIR model for age group <inline-formula><mml:math id="i84" overflow="scroll"><mml:mi>p</mml:mi></mml:math></inline-formula> with a two-dose vaccine that blocks infection.</p>
                  </caption>
                  <graphic xlink:href="pnas.2104640118fig04" id="gra4" position="float"/>
                </fig>
                <p>The mean incubation and infectious times are <inline-formula><mml:math id="i85" overflow="scroll"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="i86" overflow="scroll"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mtext>inf</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>, respectively. The variable <inline-formula><mml:math id="i87" overflow="scroll"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> represents the proportion of the subpopulation <inline-formula><mml:math id="i88" overflow="scroll"><mml:mi>p</mml:mi></mml:math></inline-formula> that is in the first stage of the vaccination process: that is, susceptible individuals in age group <inline-formula><mml:math id="i89" overflow="scroll"><mml:mi>p</mml:mi></mml:math></inline-formula> who did not receive any dose of the vaccine yet or who have been recently inoculated and the first-dose immunity is still building up. Likewise, <inline-formula><mml:math id="i90" overflow="scroll"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the proportion of susceptible individuals who are already protected by the effect of the first dose while still waiting for the second dose to be inoculated or become effective. Finally, <inline-formula><mml:math id="i91" overflow="scroll"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> represents the fraction of susceptible already protected by the full effect of the two doses. The meaning of the other compartments, <inline-formula><mml:math id="i92" overflow="scroll"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mn>3</mml:mn></mml:math></inline-formula>, is similar. The intermediate states <inline-formula><mml:math id="i93" overflow="scroll"><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="i94" overflow="scroll"><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> represent individuals in <inline-formula><mml:math id="i95" overflow="scroll"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="i96" overflow="scroll"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> for whom the <inline-formula><mml:math id="i97" overflow="scroll"><mml:mi>i</mml:mi></mml:math></inline-formula>th vaccine dose has just made effect and who are transitioning to the new states <inline-formula><mml:math id="i98" overflow="scroll"><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="i99" overflow="scroll"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, respectively. Note that they spend only half of the time in this state, as they have already spent some time in the original state before moving to the next stage.</p>
                <p>The variable <inline-formula><mml:math id="i100" overflow="scroll"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1,2</mml:mn></mml:math></inline-formula>, models the number of people from the level <inline-formula><mml:math id="i101" overflow="scroll"><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula> for which the <inline-formula><mml:math id="i102" overflow="scroll"><mml:mi>i</mml:mi></mml:math></inline-formula>th dose of the vaccine made effect at a given moment in time, afterwards their state changes and they move to the next level <inline-formula><mml:math id="i103" overflow="scroll"><mml:mi>i</mml:mi></mml:math></inline-formula>. Other transition relations can be found in <xref rid="t01" ref-type="table">Table 1</xref>, where <inline-formula><mml:math id="i104" overflow="scroll"><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> stands for the level achieved in attenuating the infection after receiving one and two doses of the vaccine. The factor <inline-formula><mml:math id="i105" overflow="scroll"><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> models the effect that behavioral patterns of the subpopulation <inline-formula><mml:math id="i106" overflow="scroll"><mml:mi>p</mml:mi></mml:math></inline-formula> have on the chances of getting infected when encountering infectious individuals (for instance, younger and active individuals being more prone to agglomerate have an increased risk of infection). The variable <inline-formula><mml:math id="i107" overflow="scroll"><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> denotes the target reproduction number that is needed at time <inline-formula><mml:math id="i108" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula> to control the spread of the disease with nonpharmaceutical measures, such as social distancing or mask wearing. Also, we note that the diagram in <xref rid="fig04" ref-type="fig">Fig. 4</xref> has no transitions from <inline-formula><mml:math id="i109" overflow="scroll"><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="i110" overflow="scroll"><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> to the lower levels because we are assuming that the meantime in these states, <inline-formula><mml:math id="i111" overflow="scroll"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="i112" overflow="scroll"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mtext>inf</mml:mtext></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:math></inline-formula>, is significantly lower than the time required for a vaccine dose to make an effect.</p>
                <table-wrap position="float" id="t01">
                  <label>Table 1.</label>
                  <caption>
                    <p>Transition ratios for levels in the diagram in <xref rid="fig04" ref-type="fig">Fig. 4</xref></p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i113" overflow="scroll">
                              <mml:msub>
                                <mml:mrow>
                                  <mml:mi>α</mml:mi>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:mi>p</mml:mi>
                                  <mml:mo>,</mml:mo>
                                  <mml:mi>i</mml:mi>
                                </mml:mrow>
                              </mml:msub>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i114" overflow="scroll">
                              <mml:msub>
                                <mml:mrow>
                                  <mml:mi>β</mml:mi>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:mi>p</mml:mi>
                                  <mml:mo>,</mml:mo>
                                  <mml:mi>i</mml:mi>
                                </mml:mrow>
                              </mml:msub>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i115" overflow="scroll">
                              <mml:msub>
                                <mml:mrow>
                                  <mml:mi>δ</mml:mi>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:mi>p</mml:mi>
                                  <mml:mo>,</mml:mo>
                                  <mml:mi>i</mml:mi>
                                </mml:mrow>
                              </mml:msub>
                            </mml:math>
                          </inline-formula>
                        </td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i116" overflow="scroll">
                              <mml:mi>i</mml:mi>
                              <mml:mo>=</mml:mo>
                              <mml:mn>1</mml:mn>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i117" overflow="scroll">
                              <mml:mfrac>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>b</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi>p</mml:mi>
                                    </mml:mrow>
                                  </mml:msub>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>r</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi>t</mml:mi>
                                    </mml:mrow>
                                  </mml:msub>
                                  <mml:mrow>
                                    <mml:mo>(</mml:mo>
                                    <mml:mrow>
                                      <mml:mn>1</mml:mn>
                                      <mml:mo>−</mml:mo>
                                      <mml:msub>
                                        <mml:mrow>
                                          <mml:mi>v</mml:mi>
                                        </mml:mrow>
                                        <mml:mrow>
                                          <mml:mi>p</mml:mi>
                                          <mml:mo>,</mml:mo>
                                          <mml:mn>1</mml:mn>
                                        </mml:mrow>
                                      </mml:msub>
                                    </mml:mrow>
                                    <mml:mo>)</mml:mo>
                                  </mml:mrow>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>T</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mtext>inf</mml:mtext>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                              </mml:mfrac>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i118" overflow="scroll">
                              <mml:mfrac>
                                <mml:mrow>
                                  <mml:mn>1</mml:mn>
                                  <mml:mo>−</mml:mo>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>v</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi>p</mml:mi>
                                      <mml:mo>,</mml:mo>
                                      <mml:mn>1</mml:mn>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>T</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi mathvariant="normal">i</mml:mi>
                                      <mml:mi mathvariant="normal">n</mml:mi>
                                      <mml:mi mathvariant="normal">c</mml:mi>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                              </mml:mfrac>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i119" overflow="scroll">
                              <mml:mfrac>
                                <mml:mrow>
                                  <mml:mn>1</mml:mn>
                                  <mml:mo>−</mml:mo>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>v</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi>p</mml:mi>
                                      <mml:mo>,</mml:mo>
                                      <mml:mn>1</mml:mn>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>T</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mtext>inf</mml:mtext>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                              </mml:mfrac>
                            </mml:math>
                          </inline-formula>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i120" overflow="scroll">
                              <mml:mi>i</mml:mi>
                              <mml:mo>=</mml:mo>
                              <mml:mn>2</mml:mn>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i121" overflow="scroll">
                              <mml:mfrac>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>a</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mn>1</mml:mn>
                                    </mml:mrow>
                                  </mml:msub>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>b</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi>p</mml:mi>
                                    </mml:mrow>
                                  </mml:msub>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>r</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi>t</mml:mi>
                                    </mml:mrow>
                                  </mml:msub>
                                  <mml:mrow>
                                    <mml:mo>(</mml:mo>
                                    <mml:mrow>
                                      <mml:mn>1</mml:mn>
                                      <mml:mo>−</mml:mo>
                                      <mml:msub>
                                        <mml:mrow>
                                          <mml:mi>v</mml:mi>
                                        </mml:mrow>
                                        <mml:mrow>
                                          <mml:mi>p</mml:mi>
                                          <mml:mo>,</mml:mo>
                                          <mml:mn>2</mml:mn>
                                        </mml:mrow>
                                      </mml:msub>
                                    </mml:mrow>
                                    <mml:mo>)</mml:mo>
                                  </mml:mrow>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>T</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mtext>inf</mml:mtext>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                              </mml:mfrac>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i122" overflow="scroll">
                              <mml:mfrac>
                                <mml:mrow>
                                  <mml:mn>1</mml:mn>
                                  <mml:mo>−</mml:mo>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>v</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi>p</mml:mi>
                                      <mml:mo>,</mml:mo>
                                      <mml:mn>2</mml:mn>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>T</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi mathvariant="normal">i</mml:mi>
                                      <mml:mi mathvariant="normal">n</mml:mi>
                                      <mml:mi mathvariant="normal">c</mml:mi>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                              </mml:mfrac>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i123" overflow="scroll">
                              <mml:mfrac>
                                <mml:mrow>
                                  <mml:mn>1</mml:mn>
                                  <mml:mo>−</mml:mo>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>v</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi>p</mml:mi>
                                      <mml:mo>,</mml:mo>
                                      <mml:mn>2</mml:mn>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>T</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mtext>inf</mml:mtext>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                              </mml:mfrac>
                            </mml:math>
                          </inline-formula>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i124" overflow="scroll">
                              <mml:mi>i</mml:mi>
                              <mml:mo>=</mml:mo>
                              <mml:mn>3</mml:mn>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i125" overflow="scroll">
                              <mml:mfrac>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>a</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mn>2</mml:mn>
                                    </mml:mrow>
                                  </mml:msub>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>b</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi>p</mml:mi>
                                    </mml:mrow>
                                  </mml:msub>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>r</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi>t</mml:mi>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>T</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mtext>inf</mml:mtext>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                              </mml:mfrac>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i126" overflow="scroll">
                              <mml:mfrac>
                                <mml:mrow>
                                  <mml:mn>1</mml:mn>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>T</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mi mathvariant="normal">i</mml:mi>
                                      <mml:mi mathvariant="normal">n</mml:mi>
                                      <mml:mi mathvariant="normal">c</mml:mi>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                              </mml:mfrac>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i127" overflow="scroll">
                              <mml:mfrac>
                                <mml:mrow>
                                  <mml:mn>1</mml:mn>
                                </mml:mrow>
                                <mml:mrow>
                                  <mml:msub>
                                    <mml:mrow>
                                      <mml:mi>T</mml:mi>
                                    </mml:mrow>
                                    <mml:mrow>
                                      <mml:mtext>inf</mml:mtext>
                                    </mml:mrow>
                                  </mml:msub>
                                </mml:mrow>
                              </mml:mfrac>
                            </mml:math>
                          </inline-formula>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
                <p>Finally, the variable <inline-formula><mml:math id="i128" overflow="scroll"><mml:msub><mml:mrow><mml:mi mathvariant="script">I</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> binds all the subpopulations together by a <italic toggle="yes">contact matrix</italic> that describes how the different age groups interact. This is a square matrix <inline-formula><mml:math id="i129" overflow="scroll"><mml:mi>C</mml:mi></mml:math></inline-formula> of dimension <inline-formula><mml:math id="i130" overflow="scroll"><mml:mi>#</mml:mi><mml:mtext>subpopulations</mml:mtext><mml:mo>×</mml:mo><mml:mi>#</mml:mi><mml:mtext>subpopulations</mml:mtext></mml:math></inline-formula> in which the entry <inline-formula><mml:math id="i131" overflow="scroll"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:math></inline-formula> represents the proportion of contacts the subpopulation <inline-formula><mml:math id="i132" overflow="scroll"><mml:mi>p</mml:mi></mml:math></inline-formula> makes with individuals of the subpopulation <inline-formula><mml:math id="i133" overflow="scroll"><mml:msup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula>. In particular, the sum by rows equals 1.0. Using this matrix, we define<disp-formula id="uneq1"><mml:math id="me1" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>≔</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mtext>proportion</mml:mtext><mml:mo> </mml:mo><mml:mtext>of</mml:mtext><mml:mo> </mml:mo><mml:mtext>the</mml:mtext><mml:mo> </mml:mo><mml:mtext>overall</mml:mtext><mml:mo> </mml:mo><mml:mtext>population</mml:mtext><mml:mo> </mml:mo><mml:mtext>that</mml:mtext><mml:mo> </mml:mo><mml:mtext>belongs</mml:mtext><mml:mo> </mml:mo><mml:mtext>to</mml:mtext><mml:mo> </mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:math></disp-formula>Additionally,<disp-formula id="uneq2"><mml:math id="me2" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi mathvariant="script">I</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munderover accentunder="false" accent="false"><mml:mrow><mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>#</mml:mi><mml:mtext>populations</mml:mtext></mml:mrow></mml:munderover><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:math></disp-formula>for which the contact matrix is<disp-formula id="uneq3"><mml:math id="me3" display="block" overflow="scroll"><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mfenced open="(" close=")"><mml:mrow><mml:mtable align="axis" equalrows="false" columnlines="none none none" equalcolumns="false" class="array"><mml:mtr><mml:mtd columnalign="left"><mml:mn>0.57</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.27</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.10</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.06</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mn>0.20</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.59</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.15</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.06</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mn>0.15</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.46</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.27</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.12</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mn>0.18</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.24</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.18</mml:mn></mml:mtd><mml:mtd columnalign="center"><mml:mn>0.39</mml:mn></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced><mml:mo>.</mml:mo></mml:math></disp-formula></p>
              </sec>
              <sec id="s15">
                <title>3B. ICU Occupation.</title>
                <p>Since the percentage of the infected population that needs intensive care at time <inline-formula><mml:math id="i134" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula> is represented by a stochastic process, a probabilistic constraint keeps the ICU bed usage below the maximum capacity, <inline-formula><mml:math id="i135" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>max</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula>. The use of a time series for the stochastic process makes it possible to reformulate the probabilistic constraint into an equivalent deterministic inequality. The detailed procedure is explained in ref. <xref rid="r19" ref-type="bibr">19</xref>; here, we mention a few key points only.</p>
                <p>Suppose infected individuals spend on average <inline-formula><mml:math id="i136" overflow="scroll"><mml:mi>ν</mml:mi><mml:mo>=</mml:mo><mml:mn>7</mml:mn></mml:math></inline-formula> days in intensive care (<xref rid="r20" ref-type="bibr">20</xref>). At time <inline-formula><mml:math id="i137" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula>, if the bed usage for a given age group <inline-formula><mml:math id="i138" overflow="scroll"><mml:mi>p</mml:mi></mml:math></inline-formula> is <inline-formula><mml:math id="i139" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, then the fraction of infected individuals who need ICU beds at time <inline-formula><mml:math id="i140" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula> can be estimated by the ratio <inline-formula><mml:math id="i141" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="script">J</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, where <inline-formula><mml:math id="i142" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi mathvariant="script">J</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> corresponds to individuals in the subpopulation <inline-formula><mml:math id="i143" overflow="scroll"><mml:mi>p</mml:mi></mml:math></inline-formula> moving to the compartment <inline-formula><mml:math id="i144" overflow="scroll"><mml:mi>R</mml:mi></mml:math></inline-formula> at time <inline-formula><mml:math id="i145" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula>. In our setting, this is equal to <inline-formula><mml:math id="i146" overflow="scroll"><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mtext>inf</mml:mtext></mml:mrow></mml:msub><mml:mfenced open="(" close=")"><mml:mrow><mml:msubsup><mml:mrow><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:mi>ν</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>I</mml:mi><mml:msubsup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfenced></mml:math></inline-formula> . The total ICU demand is distributed proportionally among the age groups using a correcting factor <inline-formula><mml:math id="i147" overflow="scroll"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> that represents the proportion of the age group that uses ICU beds, when compared with its demography. <xref rid="t02" ref-type="table">Table 2</xref> reports the corresponding data for 2010 in São Paulo state, which has 44 million inhabitants.</p>
                <table-wrap position="float" id="t02">
                  <label>Table 2.</label>
                  <caption>
                    <p>ICU demand by age for the state of São Paulo, Brazil</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i148" overflow="scroll">
                              <mml:mtable align="axis" equalrows="false" columnlines="none none none none none none none none none" equalcolumns="false" class="array">
                                <mml:mtr>
                                  <mml:mtd columnalign="center">
                                    <mml:mstyle>
                                      <mml:mtext>Population</mml:mtext>
                                    </mml:mstyle>
                                  </mml:mtd>
                                </mml:mtr>
                                <mml:mtr>
                                  <mml:mtd columnalign="center">
                                    <mml:mstyle>
                                      <mml:mtext>group,</mml:mtext>
                                    </mml:mstyle>
                                    <mml:mi>p</mml:mi>
                                  </mml:mtd>
                                </mml:mtr>
                              </mml:mtable>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i149" overflow="scroll">
                              <mml:mtable align="axis" equalrows="false" columnlines="none none none none none none none none none" equalcolumns="false" class="array">
                                <mml:mtr>
                                  <mml:mtd columnalign="center">
                                    <mml:mstyle>
                                      <mml:mtext>Age</mml:mtext>
                                    </mml:mstyle>
                                  </mml:mtd>
                                </mml:mtr>
                                <mml:mtr>
                                  <mml:mtd columnalign="center">
                                    <mml:mstyle>
                                      <mml:mtext>group,</mml:mtext>
                                      <mml:mo> </mml:mo>
                                      <mml:mtext>y</mml:mtext>
                                    </mml:mstyle>
                                  </mml:mtd>
                                </mml:mtr>
                              </mml:mtable>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">Demography, %</td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i150" overflow="scroll">
                              <mml:mtable align="axis" equalrows="false" columnlines="none none none none none none none none none" equalcolumns="false" class="array">
                                <mml:mtr>
                                  <mml:mtd columnalign="center">
                                    <mml:mstyle>
                                      <mml:mtext>Actual</mml:mtext>
                                      <mml:mo> </mml:mo>
                                      <mml:mtext>ICU</mml:mtext>
                                    </mml:mstyle>
                                  </mml:mtd>
                                </mml:mtr>
                                <mml:mtr>
                                  <mml:mtd columnalign="center">
                                    <mml:mstyle>
                                      <mml:mtext>usage</mml:mtext>
                                      <mml:mo>,</mml:mo>
                                      <mml:mo> </mml:mo>
                                      <mml:mo>%</mml:mo>
                                    </mml:mstyle>
                                  </mml:mtd>
                                </mml:mtr>
                              </mml:mtable>
                            </mml:math>
                          </inline-formula>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <inline-formula>
                            <mml:math id="i151" overflow="scroll">
                              <mml:mtable align="axis" equalrows="false" columnlines="none none none none none none none none none" equalcolumns="false" class="array">
                                <mml:mtr>
                                  <mml:mtd columnalign="center">
                                    <mml:mstyle>
                                      <mml:mtext>Correcting</mml:mtext>
                                    </mml:mstyle>
                                  </mml:mtd>
                                </mml:mtr>
                                <mml:mtr>
                                  <mml:mtd columnalign="center">
                                    <mml:mstyle>
                                      <mml:mtext>factor,</mml:mtext>
                                    </mml:mstyle>
                                    <mml:msub>
                                      <mml:mrow>
                                        <mml:mi>γ</mml:mi>
                                      </mml:mrow>
                                      <mml:mrow>
                                        <mml:mi>p</mml:mi>
                                      </mml:mrow>
                                    </mml:msub>
                                  </mml:mtd>
                                </mml:mtr>
                              </mml:mtable>
                            </mml:math>
                          </inline-formula>
                        </td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">1</td>
                        <td align="center" rowspan="1" colspan="1">0–19</td>
                        <td align="center" rowspan="1" colspan="1">29</td>
                        <td align="center" rowspan="1" colspan="1">2</td>
                        <td align="center" rowspan="1" colspan="1">0.06</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">2</td>
                        <td align="center" rowspan="1" colspan="1">20–49</td>
                        <td align="center" rowspan="1" colspan="1">48</td>
                        <td align="center" rowspan="1" colspan="1">28</td>
                        <td align="center" rowspan="1" colspan="1">0.58</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">3</td>
                        <td align="center" rowspan="1" colspan="1">50–64</td>
                        <td align="center" rowspan="1" colspan="1">14</td>
                        <td align="center" rowspan="1" colspan="1">30</td>
                        <td align="center" rowspan="1" colspan="1">2.06</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">4</td>
                        <td align="center" rowspan="1" colspan="1">65–90</td>
                        <td align="center" rowspan="1" colspan="1">8</td>
                        <td align="center" rowspan="1" colspan="1">40</td>
                        <td align="center" rowspan="1" colspan="1">5.16</td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
                <p>To obtain the time series parameters, we computed the history of ratios from the last quarter of 2020 until the end of January 2021 using official records of São Paulo state. Autoregressive models with lag up to two and no trend appeared as the best ones in terms of Bayesian information criterion. Back testing over January gave mean absolute percentage error values of 1.88, 2.02, and 9.84% for the lags two, one, and zero, respectively, with an approximate normal-looking shape for the residual histograms. When performing out of sample simulations until May 2021, we noticed that both trajectories with positive lags stabilized at the same value as those with zero lag. Since the mean absolute percentage error accuracy of the latter model was acceptable and the optimization problem covers a long time horizon, we chose the simplest time series, with lag zero, for the constraint. After scaling back, this procedure gave the following simple model, <inline-formula><mml:math id="i152" overflow="scroll"><mml:msup><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">u</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>∼</mml:mo><mml:mo> </mml:mo><mml:mi mathvariant="script">N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> for <inline-formula><mml:math id="i153" overflow="scroll"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="i154" overflow="scroll"><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>ω</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.002</mml:mn></mml:math></inline-formula>. After these parameters are known, the pro rata per subpopulation is done as explained above to make explicit the probabilistic constraints<disp-formula id="uneq4"><mml:math id="me4" display="block" overflow="scroll"><mml:mi mathvariant="double-struck">P</mml:mi><mml:mfenced open="[" close="]"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">u</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:munderover accentunder="false" accent="false"><mml:mrow><mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:munderover><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi mathvariant="script">J</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:mo>≤</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mo>max</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfenced><mml:mo>≥</mml:mo><mml:mi>δ</mml:mi><mml:mo>,</mml:mo></mml:math></disp-formula>which ensure the hospital capacity will not be exceeded, with <inline-formula><mml:math id="i155" overflow="scroll"><mml:mi>δ</mml:mi></mml:math></inline-formula> probability. In the experiments, we used <inline-formula><mml:math id="i156" overflow="scroll"><mml:mi>δ</mml:mi><mml:mo>=</mml:mo><mml:mn>95</mml:mn><mml:mi>%</mml:mi></mml:math></inline-formula>. The deterministic equivalent of the chance constraint is an affine inequality of the form <inline-formula><mml:math id="i157" overflow="scroll"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi mathvariant="script">J</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:mo>≤</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mo>max</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:math></inline-formula>, where the term <inline-formula><mml:math id="i158" overflow="scroll"><mml:mi mathvariant="normal">Δ</mml:mi></mml:math></inline-formula> involves the inverse cumulative function of the standard Gaussian distribution. Ref. <xref rid="r19" ref-type="bibr">19</xref> has more details.</p>
              </sec>
              <sec id="s16">
                <title>3C. Optimizing on Multiple Populations.</title>
                <p>Given the models for ICU demand and vaccine supplies, the optimization algorithm finds the best strategy for vaccination and social distancing that simultaneously avoids the collapse of the health care infrastructure and controls the pandemic in the shortest amount of time. To achieve these goals we initially use an objective function <inline-formula><mml:math id="i159" overflow="scroll"><mml:mi>f</mml:mi></mml:math></inline-formula> that encourages large values of the reproduction number <inline-formula><mml:math id="i160" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. The optimization is done over the decision variables <inline-formula><mml:math id="i161" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="i162" overflow="scroll"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="i163" overflow="scroll"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> that control the trajectories of the state variables, defined by the different SEIR compartments. The system of differential equations of the modified SEIR dynamic illustrated by the diagram in <xref rid="fig01" ref-type="fig">Fig. 1</xref> is discretized using central finite differences over a horizon of <inline-formula><mml:math id="i164" overflow="scroll"><mml:mi>K</mml:mi></mml:math></inline-formula> days (<inline-formula><mml:math id="i165" overflow="scroll"><mml:mi>K</mml:mi><mml:mo>=</mml:mo><mml:mn>364</mml:mn></mml:math></inline-formula> in the simulations). Letting <inline-formula><mml:math id="i166" overflow="scroll"><mml:mi>c</mml:mi></mml:math></inline-formula> denote the vector whose components are the control variables <inline-formula><mml:math id="i167" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, and <inline-formula><mml:math id="i168" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, for <inline-formula><mml:math id="i169" overflow="scroll"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>K</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="i170" overflow="scroll"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>#</mml:mi><mml:mtext>subpopulations</mml:mtext></mml:math></inline-formula>, and letting <inline-formula><mml:math id="i171" overflow="scroll"><mml:mi mathvariant="normal">s</mml:mi></mml:math></inline-formula> denote the state vector, with all the SEIR compartments for all subpopulations, the optimization problem has the abstract form<disp-formula id="uneq5"><mml:math id="me5" display="block" overflow="scroll"><mml:mtable columnalign="left" class="align-star"><mml:mtr><mml:mtd columnalign="right"><mml:munder><mml:mrow><mml:mo largeop="true" movablelimits="false" symmetric="true">max</mml:mo></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:munder></mml:mtd><mml:mtd columnalign="left"><mml:mo> </mml:mo><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mtext>s.t.</mml:mtext></mml:mtd><mml:mtd columnalign="left"><mml:mo> </mml:mo><mml:mi>s</mml:mi><mml:mo>∈</mml:mo><mml:mtext>Discretization</mml:mtext><mml:mo> </mml:mo><mml:mtext>of</mml:mtext><mml:mo> </mml:mo><mml:mtext>SEIR</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"/><mml:mtd columnalign="left"><mml:mo> </mml:mo><mml:mi>c</mml:mi><mml:mo>∈</mml:mo><mml:mtext>logistic</mml:mtext><mml:mo> </mml:mo><mml:mtext>bounds</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"/><mml:mtd columnalign="left"><mml:mo> </mml:mo><mml:mi>s</mml:mi><mml:mo>∈</mml:mo><mml:mtext>ICU</mml:mtext><mml:mo> </mml:mo><mml:mtext>usage</mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>where the latter set represents the reformulation of the probabilistic constraint defined in Section 3B. Logistic relations on the control variables refer to the number of vaccines available each day taking into account both vaccine availability and the inoculation capacity. Specific time windows for giving the second dose, say <inline-formula><mml:math id="i172" overflow="scroll"><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>min</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>max</mml:mo></mml:mrow></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:math></inline-formula>, are enforced by requiring the total number of second doses applied up to day <inline-formula><mml:math id="i173" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula> to be smaller than or equal to the total number of first doses administered up to the day <inline-formula><mml:math id="i174" overflow="scroll"><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>min</mml:mo></mml:mrow></mml:msub></mml:math></inline-formula>. This constraint ensures that no second doses are given before possible. On the other hand, we also limit the total number of second doses given until <inline-formula><mml:math id="i175" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula> to be at least the total number of first doses administered up to <inline-formula><mml:math id="i176" overflow="scroll"><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>max</mml:mo></mml:mrow></mml:msub></mml:math></inline-formula>, ensuring that the second doses are applied within the desired time window. In our implementation, <inline-formula><mml:math id="i177" overflow="scroll"><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>min</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>28</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="i178" overflow="scroll"><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>max</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>84</mml:mn></mml:math></inline-formula>.</p>
                <p>The objective function to minimize is the sum of differences <inline-formula><mml:math id="i179" overflow="scroll"><mml:msubsup><mml:mrow><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, where <inline-formula><mml:math id="i180" overflow="scroll"><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2.5</mml:mn></mml:math></inline-formula> is the basal reproduction number of the virus used in the simulation (<xref rid="r21" ref-type="bibr">21</xref>, <xref rid="r22" ref-type="bibr">22</xref>). The rationale is to allow the population to circulate freely. To discourage bang-bang controls, we add to the objective a total quadratic variation term for the number of doses applied at each population each day. This term results in vaccination profiles that are easier to visualize and understand. After this first optimization step, we perform a second optimization that tries to minimize ICU usage without deteriorating the computed <inline-formula><mml:math id="i181" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> profile. To achieve this, we add the constraint<disp-formula id="uneq6"><mml:math id="me6" display="block" overflow="scroll"><mml:munderover accentunder="false" accent="false"><mml:mrow><mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:munderover><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo>≥</mml:mo><mml:munderover accentunder="false" accent="false"><mml:mrow><mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:munderover><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:math></disp-formula>and we switch the objective to minimize the estimated ICU usage.</p>
                <p>These problems are large-scale nonconvex quadratic optimization problems. They are formulated using the JuMP (<xref rid="r23" ref-type="bibr">23</xref>) modeling language and solved using the nonlinear optimization solver Ipopt (<xref rid="r24" ref-type="bibr">24</xref>). The typical solution time is around 5 min on a desktop computer with a Ryzen 1700X processor.</p>
              </sec>
            </sec>
          </body>
          <back>
            <ack>
              <p>This work was supported by Center for Research in Mathematics Applied to Industry, Fundação de Amparo à Pesquisa do Estado de São Paulo Grants 2013/07375-0 and 2018/24293-0; the Royal Society London; Brazilian National Council for Scientific and Technological Development Grants 301778/2017-5, 302836/2018-7, 304301/2019-1, 306090/2019-0, 302912/2019-3, and 403679/2020-6; Serrapilheira Institute Grant Serra-1709-16124; and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro Grant E-26/202.828/2017.</p>
            </ack>
            <fn-group>
              <fn fn-type="COI-statement">
                <p>The authors declare no competing interest.</p>
              </fn>
              <fn fn-type="other">
                <p>This article is a PNAS Direct Submission.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability" id="s17">
              <title>Data Availability</title>
              <p>Input files or sets of input parameters as well as the source code have been deposited in GitHub (<ext-link xlink:href="https://github.com/pjssilva/Robot-vaccine" ext-link-type="uri" xlink:show="new">https://github.com/pjssilva/Robot-vaccine</ext-link>).</p>
            </sec>
            <ref-list>
              <ref id="r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. D.</given-names><surname>Paltiel</surname></string-name>, <string-name><given-names>A.</given-names><surname>Zheng</surname></string-name>, <string-name><given-names>J. L.</given-names><surname>Schwartz</surname></string-name></person-group>, <article-title>Speed versus efficacy: Quantifying potential tradeoffs in COVID-19 vaccine deployment</article-title>. <source>Ann. Intern. Med.</source><volume>174</volume>, <fpage>568</fpage>–<lpage>570</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33395345</pub-id></mixed-citation>
              </ref>
              <ref id="r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. V.</given-names><surname>Barnabas</surname></string-name>, <string-name><given-names>A.</given-names><surname>Wald</surname></string-name></person-group>, <article-title>A public health COVID-19 vaccination strategy to maximize the health gains for every single vaccine dose</article-title>. <source>Ann. Intern. Med.</source><volume>174</volume>, <fpage>552</fpage>–<lpage>553</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33395339</pub-id></mixed-citation>
              </ref>
              <ref id="r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The Lancet Infectious Diseases</collab></person-group>, <article-title>An exceptional vaccination policy in exceptional circumstances</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume>, <fpage>149</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33460564</pub-id></mixed-citation>
              </ref>
              <ref id="r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names><surname>Fontanet</surname></string-name><etal/></person-group>., <article-title>SARS-CoV-2 variants and ending the COVID-19 pandemic</article-title>. <source>Lancet</source><volume>397</volume>, <fpage>952</fpage>–<lpage>954</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33581803</pub-id></mixed-citation>
              </ref>
              <ref id="r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names><surname>Lipsitch</surname></string-name>, <string-name><given-names>N. E.</given-names><surname>Dean</surname></string-name></person-group>, <article-title>Understanding COVID-19 vaccine efficacy</article-title>. <source>Science</source><volume>370</volume>, <fpage>763</fpage>–<lpage>765</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">33087460</pub-id></mixed-citation>
              </ref>
              <ref id="r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. R.</given-names><surname>MacIntyre</surname></string-name>, <string-name><given-names>V.</given-names><surname>Costantino</surname></string-name>, <string-name><given-names>M.</given-names><surname>Trent</surname></string-name></person-group>, <article-title>Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia</article-title>. <source>Vaccine</source>, <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.04.042</pub-id> (<year>2021</year>).</mixed-citation>
              </ref>
              <ref id="r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names><surname>Matrajt</surname></string-name>, <string-name><given-names>J.</given-names><surname>Eaton</surname></string-name>, <string-name><given-names>T.</given-names><surname>Leung</surname></string-name>, <string-name><given-names>E. R.</given-names><surname>Brown</surname></string-name></person-group>, <article-title>Vaccine optimization for COVID-19: Who to vaccinate first?</article-title><source>Sci. Adv.</source><volume>7</volume>, <fpage>eabf1374</fpage>(<year>2020</year>).<pub-id pub-id-type="pmid">33536223</pub-id></mixed-citation>
              </ref>
              <ref id="r8">
                <label>8</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><given-names>L.</given-names><surname>Matrajt</surname></string-name><etal/></person-group>., <article-title>Optimizing vaccine allocation for COVID-19 vaccines: Critical role of single-dose vaccination</article-title>. <comment>medRxiv</comment> [Preprint] (<year>2021</year>). <pub-id pub-id-type="doi">10.1101/2020.12.31.20249099</pub-id> (Accessed 11 February 2021).</mixed-citation>
              </ref>
              <ref id="r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. L.</given-names><surname>Chang</surname></string-name>, <string-name><given-names>N.</given-names><surname>Harding</surname></string-name>, <string-name><given-names>C.</given-names><surname>Zachreson</surname></string-name>, <string-name><given-names>O. M.</given-names><surname>Cliff</surname></string-name>, <string-name><given-names>M.</given-names><surname>Prokopenko</surname></string-name></person-group>, <article-title>Modelling transmission and control of the COVID-19 pandemic in Australia</article-title>. <source>Nat. Commun.</source><volume>11</volume>, <fpage>5710</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">33177507</pub-id></mixed-citation>
              </ref>
              <ref id="r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names><surname>Dehning</surname></string-name><etal/></person-group>., <article-title>Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions</article-title>. <source>Science</source><volume>369</volume>, <fpage>eabb9789</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32414780</pub-id></mixed-citation>
              </ref>
              <ref id="r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names><surname>Aziz</surname></string-name><etal/></person-group>., <article-title>Managing ICU surge during the COVID-19 crisis: Rapid guidelines</article-title>. <source>Intensive Care Med.</source><volume>46</volume>, <fpage>1303</fpage>–<lpage>1325</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32514598</pub-id></mixed-citation>
              </ref>
              <ref id="r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names><surname>Voysey</surname></string-name><etal/></person-group>., <article-title>Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials</article-title>. <source>Lancet</source><volume>397</volume>, <fpage>881</fpage>–<lpage>891</lpage>(<year>2021</year>).<pub-id pub-id-type="pmid">33617777</pub-id></mixed-citation>
              </ref>
              <ref id="r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names><surname>Bieniasz</surname></string-name></person-group>, <article-title>The case against delaying SARS-CoV-2 mRNA vaccine boosting doses</article-title>. <source>Clin. Infect. Dis.</source>, <fpage>ciab070</fpage> (<year>2021</year>).<pub-id pub-id-type="doi">10.1093/cid/ciab070</pub-id>.</mixed-citation>
              </ref>
              <ref id="r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names><surname>Cobey</surname></string-name>, <string-name><given-names>D. B.</given-names><surname>Larremore</surname></string-name>, <string-name><given-names>Y. H.</given-names><surname>Grad</surname></string-name>, <string-name><given-names>M.</given-names><surname>Lipsitch</surname></string-name></person-group>, <article-title>Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination</article-title>. <source>Nat. Rev. Immunol.</source><volume>21</volume>, <fpage>330</fpage>–<lpage>335</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33795856</pub-id></mixed-citation>
              </ref>
              <ref id="r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. A.</given-names><surname>Kennedy</surname></string-name>, <string-name><given-names>A. F.</given-names><surname>Read</surname></string-name></person-group>, <article-title>Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>115</volume>, <fpage>12878</fpage>–<lpage>12886</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30559199</pub-id></mixed-citation>
              </ref>
              <ref id="r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. A.</given-names><surname>Kennedy</surname></string-name>, <string-name><given-names>A. F.</given-names><surname>Read</surname></string-name></person-group>, <article-title>Why does drug resistance readily evolve but vaccine resistance does not?</article-title><source>Proc. Biol. Sci.</source><volume>284</volume>, <fpage>20162562</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28356449</pub-id></mixed-citation>
              </ref>
              <ref id="r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. M.</given-names><surname>Saad-Roy</surname></string-name><etal/></person-group>., <article-title>Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes</article-title>. <source>Science</source><volume>372</volume>, <fpage>363</fpage>–<lpage>370</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33688062</pub-id></mixed-citation>
              </ref>
              <ref id="r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>O. T.</given-names><surname>Ranzani</surname></string-name><etal/></person-group>., <article-title>Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: A retrospective analysis of nationwide data</article-title>. <source>Lancet Respir. Med.</source><volume>9</volume>, <fpage>407</fpage>–<lpage>418</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33460571</pub-id></mixed-citation>
              </ref>
              <ref id="r19">
                <label>19</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><given-names>L. G.</given-names><surname>Nonato</surname></string-name>, <string-name><given-names>P.</given-names><surname>Peixoto</surname></string-name>, <string-name><given-names>T.</given-names><surname>Pereira</surname></string-name>, <string-name><given-names>C.</given-names><surname>Sagastizábal</surname></string-name>, <string-name><given-names>P. J. S.</given-names><surname>Silva</surname></string-name></person-group>, Data from “Robot Dance: A mathematical optimization platform for intervention against COVID-19 in a complex network.” Optimization Online. <ext-link xlink:href="http://www.optimization-online.org/DB_HTML/2020/10/8054.html" ext-link-type="uri" xlink:show="new">http://www.optimization-online.org/DB_HTML/2020/10/8054.html</ext-link>. Accessed 1 June 2020.</mixed-citation>
              </ref>
              <ref id="r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. V. M. d. S.</given-names><surname>Noronha</surname></string-name><etal/></person-group>., <article-title>Pandemia por COVID-19 no Brasil: Análise da demanda e da oferta de leitos hospitalares e equipamentos de ventilação assistida segundo diferentes cenários</article-title>. <source>Cad. Saude Publica</source><volume>36</volume>, <fpage>e00115320</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32578805</pub-id></mixed-citation>
              </ref>
              <ref id="r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. S.</given-names><surname>Candido</surname></string-name><etal/></person-group>., <article-title>Evolution and epidemic spread of SARS-CoV-2 in Brazil</article-title>. <source>Science</source><volume>369</volume>, <fpage>1255</fpage>–<lpage>1260</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32703910</pub-id></mixed-citation>
              </ref>
              <ref id="r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names><surname>Ferretti</surname></string-name><etal/></person-group>., <article-title>Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing</article-title>. <source>Science</source><volume>368</volume>, <fpage>eabb6936</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32234805</pub-id></mixed-citation>
              </ref>
              <ref id="r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>I.</given-names><surname>Dunning</surname></string-name>, <string-name><given-names>J.</given-names><surname>Huchette</surname></string-name>, <string-name><given-names>M.</given-names><surname>Lubin</surname></string-name></person-group>, <article-title>JuMP: A modeling language for mathematical optimization</article-title>. <source>SIAM Rev.</source><volume>59</volume>, <fpage>295</fpage>–<lpage>320</lpage> (<year>2017</year>).</mixed-citation>
              </ref>
              <ref id="r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names><surname>Wächter</surname></string-name>, <string-name><given-names>L. T.</given-names><surname>Biegler</surname></string-name></person-group>, <article-title>On the implementation of an interior-point filter line-search algorithm for large-scale nonlinear programming</article-title>. <source>Math. Program.</source><volume>106</volume>, <fpage>25</fpage>–<lpage>57</lpage> (<year>2006</year>).</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
